Andrea Tan
Stock Analyst at Goldman Sachs
(0.29)
# 4,428
Out of 4,651 analysts
62
Total ratings
47.9%
Success rate
-10.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintained: Hold | $51 → $68 | $69.20 | -1.73% | 7 | Feb 5, 2026 | |
| KRYS Krystal Biotech | Reiterated: Buy | $193 → $327 | $332.27 | -1.59% | 3 | Jan 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $567 | $507.56 | +11.71% | 9 | Aug 18, 2025 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $16 → $8 | $6.98 | n/a | 7 | Jun 3, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Hold | $28 → $26 | $86.64 | n/a | 4 | Mar 10, 2025 | |
| KOD Kodiak Sciences | Reiterated: Sell | $2 | $41.35 | n/a | 7 | Sep 24, 2024 | |
| INSM Insmed | Maintained: Buy | $102 → $103 | $123.74 | n/a | 8 | Aug 9, 2024 | |
| SGMT Sagimet Biosciences | Downgraded: Hold | $23 → $6 | $10.55 | n/a | 3 | Jun 28, 2024 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Buy | $169 | $244.96 | n/a | 1 | Jun 5, 2024 | |
| RLMD Relmada Therapeutics | Downgraded: Sell | $8 → $2 | $4.80 | n/a | 5 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $48.74 | n/a | 1 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $24 | $11.38 | n/a | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $4 | $2.57 | n/a | 3 | Jan 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $4 | $23.03 | n/a | 2 | May 24, 2022 |
Tarsus Pharmaceuticals
Feb 5, 2026
Maintained: Hold
Price Target: $51 → $68
Current: $69.20
Upside: -1.73%
Krystal Biotech
Jan 30, 2026
Reiterated: Buy
Price Target: $193 → $327
Current: $332.27
Upside: -1.59%
Madrigal Pharmaceuticals
Aug 18, 2025
Reiterated: Buy
Price Target: $567
Current: $507.56
Upside: +11.71%
Iovance Biotherapeutics
Jun 3, 2025
Reiterated: Buy
Price Target: $16 → $8
Current: $6.98
Upside: n/a
Arrowhead Pharmaceuticals
Mar 10, 2025
Reiterated: Hold
Price Target: $28 → $26
Current: $86.64
Upside: n/a
Kodiak Sciences
Sep 24, 2024
Reiterated: Sell
Price Target: $2
Current: $41.35
Upside: n/a
Insmed
Aug 9, 2024
Maintained: Buy
Price Target: $102 → $103
Current: $123.74
Upside: n/a
Sagimet Biosciences
Jun 28, 2024
Downgraded: Hold
Price Target: $23 → $6
Current: $10.55
Upside: n/a
Jazz Pharmaceuticals
Jun 5, 2024
Initiated Coverage: Buy
Price Target: $169
Current: $244.96
Upside: n/a
Relmada Therapeutics
Jun 5, 2024
Downgraded: Sell
Price Target: $8 → $2
Current: $4.80
Upside: n/a
Jan 9, 2024
Reiterated: Hold
Price Target: n/a
Current: $48.74
Upside: n/a
Aug 4, 2023
Maintained: Buy
Price Target: $30 → $24
Current: $11.38
Upside: n/a
Jan 10, 2023
Maintained: Sell
Price Target: $4
Current: $2.57
Upside: n/a
May 24, 2022
Maintained: Hold
Price Target: $6 → $4
Current: $23.03
Upside: n/a